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Background: Outcomes of intravitreal antivascular endothelial growth factor injections are 
variable among patients with diabetic macular edema (DME). The aim of this study was to deter-
mine the ocular and systemic predictors of DME response to intravitreal bevacizumab (IVB).
Methods: Retrospective review over 2 years of 78 eyes from 54 patients. An anatomical 
response to IVB was defined as a 20% reduction in central macula thickness after the first 
course (three injections) of IVB.
Results: Twenty-eight percent of patients had an anatomical response after the first course of 
IVB. Systemic hypertension (odds ratio, 95% confidence interval: 12.1, 0.7–21) was a statisti-
cally significant predictor (P=0.025) of a good response to IVB, whereas previous macular 
laser was a statistically significant (P=0.0005) predictor of a poor response (0.07, 0.01–0.32). 
Sixty-eight percent of eyes underwent subsequent treatment for DME after the first course of 
IVB. The visual acuity gain at 24 months in hypertensive (0.7±3.6 letters) and nonhypertensive 
(5.2±3.7 letters) patients was not significantly different (P=0.41).
Conclusion: Hypertension and previous macular laser were positive and negative predictors of 
response to IVB, respectively. However, long-term visual acuity changes were not significantly 
different between eyes with and without systemic hypertension.
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Background
Diabetic macular edema (DME) is one of the leading causes of visual impairment.1 
Traditionally, macular laser photocoagulation has been the gold standard treatment 
for managing DME based on results from the Early Treatment Diabetic Retinopathy 
Study (ETDRS).2 However, intravitreal injections of vascular endothelial growth factor 
(VEGF) inhibitors have demonstrated better outcomes when compared to laser photoco-
agulation, with good quality evidence from several randomized controlled trials.3–5
Bevacizumab is an anti-VEGF antibody available as an off-label therapy in the 
UK for DME; it is considerably cheaper than the licensed drug ranibizumab and has 
similar gains in visual acuity (VA) compared to other intravitreal anti-VEGF agents 
for most subgroup of patients.5,6 Long-term results with intravitreal bevacizumab 
(IVB) at 24 months have demonstrated statistically significant gains in VA compared 
to laser, with patients receiving a median number of 13 treatments during this time.7 
Outcomes seem to be variable among patients, so recent reports have focused on 
identifying predictors of response. These have looked at systemic8,9 or ocular factors,10 
but not in conjunction with each other, which could be important since these factors 
may be interrelated.
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The aim of this study is to address these issues and 
determine the ocular and systemic predictors of DME 
response to IVB in a large cohort of patients.
Methods
We conducted a retrospective consecutive case series review 
of 53 patients (74 eyes) who received one or more courses of 
IVB injections (Avastin, Roche Registration Limited, Welwyn 
Garden City, UK) for the treatment of DME at the Royal Surrey 
County Hospital (Guildford, UK) during the period May 1, 2011 
to December 31, 2013, who had at least 1 year of follow-up. 
Each IVB injection (1.25 mg/0.05 mL) was prepared by the 
hospital pharmacy as a prefilled syringe containing 0.10 mL, 
with only 0.05 mL being injected into an eye. This study was 
approved by the Royal Surrey County Hospital Research Ethics 
Committee (outcomes of retinal disease: RSCH/12DEV0010). 
Due to the observational and retrospective nature of the study, 
for which data were obtained from review of medical charts, 
with no intervention or deliberate modification of treatment, 
patient informed consent was waived by the committee.
Patients who had recurrent/persistent DME after laser 
photocoagulation for DME or patients who had DME close to 
the fovea were included in the study. Patients were excluded 
if they had ,12 months of follow-up from their first injec-
tion. There were no patients who had previously received 
other intravitreal therapies or had other ophthalmic diagnoses 
related to macular edema.
The injections were performed under sterile conditions, 
with topical anesthesia using a standardized technique, includ-
ing the use of topical povidone-iodine 5% and a lid speculum.11 
The injections were placed with a 30-gauge needle through 
the supra- or infratemporal quadrant. Topical ciprofloxacin 
was given four times a day for 5 days postoperatively.
Baseline ocular and systemic comorbidities were recorded, 
as were previous treatments with laser photocoagulation. 
Baseline and follow-up visits included ETDRS VA charts, 
clinical examination, intraocular pressure (IOP) measurement, 
optical coherence tomography (OCT) scanning using a Top-
Con 3D OCT-1000 scanner (Topcon Corp., Tokyo, Japan). 
Fundus fluorescein angiography using a digital retinal camera 
system (Topcon TRC 50IX, Topcon Medical Systems Inc., 
Paramus, NJ, USA) was performed at the baseline visit.
A course of injections included three injections given 
4 weeks apart and was followed by a doctor’s review with an 
OCT scan 4 weeks after the third injection. A repeat course 
of injections was given if the patient had any clinical/OCT 
evidence of DME. During the study period, four eyes received 
panretinal laser photocoagulation and one eye underwent 
cataract surgery. The study period ended at the last follow-up 
or at the time of eyes subsequently receiving other intravitreal 
therapies or macula laser for DME, whichever was sooner.
We classified anatomical responders as those with 
evidence of a central macula thickness (CMT) reduction 
of $20% after the first course of three injections, in line with 
previous studies of anti-VEGF intravitreal therapy.9,12
OCT analysis
OCT scans from every visit were reviewed to determine 
the CMT. OCT scans at baseline and at 12 months were 
also reviewed to determine the status of the inner segment–
outer segment junction. This was taken as the first hyper-
reflective line above the retinal pigment epithelium on the 
OCT scan, and is believed to represent the integrity of the 
photoreceptor layer.13,14 A three-step scale was used to 
evaluate the line: normal, abnormal (speckled or irregular 
line), and absent.
Fluorescein angiography
Foveal avascular zone outline was classified according to the 
ETDRS grading system: from 0 (normal), to 1 (questionable), 
2 (less than half the original circumference destroyed), 
3 (more than half the contour destroyed but some remnants 
remain), and 4 (capillary outline completely destroyed).15
statistical analysis
All data was entered into a Microsoft Excel 2010 spreadsheet 
(Microsoft Corporation, Redmond, WA, USA). Analyses and 
graphs were constructed using GraphPad Prism v5.01 (La 
Jolla, CA, USA), and PASW Statistics 18 (v18.0.0; SPSS 
Inc., Chicago, IL, USA). A P-value #0.05 was accepted as 
statistically significant. Changes in variables were compared 
by Wilcoxon and Mann–Whitney test; proportions between 
groups were compared using the χ2 test, Fisher’s test, or 
McNemar test. Logistic regression was used to evaluate 
potential predictors of response, generating odds ratios.
Results
A total of 74 eyes from 53 patients were included in the 
study. The median total follow-up time after the first injection 
of IVB was 23.5 months (range, 12–34 months). The total 
number of IVB injections during the study period was 345. 
Baseline patient characteristics are summarized in Table 1. 
Sixty-one percent of eyes received previous macular laser for 
DME, with a median of one laser session (range, 1–7).
Response to first course
Figure 1 illustrates the distribution of the % change in CMT 
after the first course of IVB. Twenty-three percent of eyes had 
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a reduction in CMT of .20%. In line with the previous stud-
ies, these patients were regarded as anatomical responders. 
After the first course, a gain of $5 letters was seen in 43% 
of anatomical responders and 32% of nonresponders.
The mean baseline CMT was significantly higher 
(P=0.0350) for responders (456±4.1 µm, mean ± standard 
error of the mean) than nonresponders (380±17.2 µm). 
The mean baseline VA was not significantly different 
(P=0.976) for responders (62.4±4.5 letters) and nonre-
sponders (62.3±2.5 letters).
Predictors of response
Table 2 shows a univariate analysis of potential predictors 
of response to the first course of IVB. A multivariate logistic 
regression analysis was not possible due to the number of 
subjects. Systemic hypertension was a statistically significant 
(P=0.025) predictor of response to IVB, increasing the odds 
of response to over 12 times compared to not being hyperten-
sive. The mean baseline CMT was not significantly different 
(P=0.0597) between hypertensive patients (413±18.5 µm) 
and nonhypertensive patients (366±30.5 µm).
Previous macula laser was a statistically significant 
(P=0.0005) predictor of poor response (odds ratio =0.07). The 
mean baseline CMT was not significantly different (P=0.59) 
between patients who had previous laser (414±39.4 µm) and 
no previous laser (394±16.9 µm).
long-term outcomes
Sixty-eight percent of eyes underwent subsequent treatment 
for DME after the first course of IVB. Long-term VA changes 
in eyes that did and did not achieve an anatomical response 
after the first course of IVB are demonstrated in Figure 2. 
Although, at 12 months, the mean VA gain was lower in the 
responder group (0.4±5.4 letters) vs nonresponders (3.4±1.8 
letters), this was not statistically significant (P=0.86). This 
finding along with the wide error bars in the responder group 
Table 1 Baseline characteristics of patients
Characteristics All patients
age, years; median (range) 65 (23–86)
sex (%)
Female 31
Male 69
Type of DM (%)
Type 1 12
Type 2 88
DM treatment (%)
insulin 24
Tablets 14
Both 62
Duration of DM, years; median (range) 13 (2–60)
nephropathy (%) 13
Mean hba1c (sD) 7.74 (2.13)
Mean systolic BP (sD) 150 (21)
Median baseline visual acuity, eTDrs letters (range) 70 (0–85)
Mean baseline central macular thickness, µm (sD) 394 (121)
Duration of DMe, months; (median, range) 14 (0–118)
Previous macular laser (%) 61
Previous PrP laser (%) 23
retinopathy grade (%)
Mild/moderate 64
severe/PDr 18
Treated PDr 18
lens status (%)
Phakic 77
Pseudophakic 23
OCT morphology (%)
Cystoid 81
Diffuse retinal thickening 13
serous detachment 6
Abbreviations: BP, blood pressure; DM, diabetes mellitus; DMe, diabetic macular 
edema; eTDrs, early Treatment Diabetic retinopathy study; OCT, optical 
coherence tomography; PDr, proliferative diabetic retinopathy; PrP, panretinal 
photocoagulation; sD, standard deviation.
Figure 1 Distribution of the change in CMT after the first course of intravitreal 
bevacizumab injections.
Abbreviation: CMT, central macular thickness.
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Table 2 Predictors of response after first course of intravitreal 
bevacizumab injections in DMe patients
Factor Unadjusted
Odds ratio  
(95% CI)
P-value
Duration of DMe .12 months 0.57 (1.7–1.9) 0.54
Baseline hba1c .7.4% 1.9 (0.47–7.6) 0.48
Diabetic treatment insulin vs no insulin 1.7 (0.6–5.3) 0.40
hypertension 12.1 (0.7–219) 0.025*
smoking 0.61 (0.1–3.3) 0.71
ischemic heart disease 4.8 (0.7–31.9) 0.12
nephropathy 2.25 (0.45–11.3) 0.38
Dr grade PDr (prior PrP) 3.5 (1.1–11.2) 0.065
Previous macula laser 0.07 (0.01–0.32) 0.0005*
Foveal avascular zone grade .2 1.7 (0.3–9.5) 0.70
OCT is-Os junction present  
vs absent/ abnormal
0.85 (0.28–2.6) 0.78
OCT morphology subretinal fluid vs no 
subretinal fluid
3.1 (0.4–23.9) 0.30
Note: *P,0.05.
Abbreviations: CI, confidence interval; DME, diabetic macular edema; DR, diabetic 
retinopathy; is-Os, inner segment outer segment; OCT, optical coherence tomo-
graphy; PDr, proliferative diabetic retinopathy; PrP, panretinal photo coagulation.
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suggests that changes in CMT and best corrected VA do 
not always correlate with each other initially. However, at 
24 months, there was a significant difference (P,0.0001) in 
VA gain in the responders (14.8±3.7 letters) vs nonresponders 
(−0.8±3.4 letters).
The VA gain at 24 months in hypertensive (0.7±3.6 let-
ters) and nonhypertensive (5.2±3.7 letters) patients was also 
not significantly different (P=0.41).
Discussion
This study demonstrates that, in a large cohort of DME 
patients, only 23% of eyes showed a response via a reduction 
in CMT (.20%) after the first course of IVB, with hyperten-
sion and previous macular laser being statistically significant 
positive and negative predictors of response, respectively. 
Long-term VA changes with subsequent IVB courses were 
similar in responders and nonresponders, but responders had 
a significantly greater gain in VA at 24 months.
In the bevacizumab or laser therapy in DME treatment 
(BOLT) study, almost 38% of eyes receiving IVB (total 
34 eyes that completed 24 months follow-up) had a response 
(CMT reduction .20%) after the first course.9 In our study, 
only 23% of eyes achieved this. The lower mean baseline 
CMT in our cohort could have been attributed to a “ceiling” 
effect whereby the relative CMT change would have been 
less. Indeed, in our cohort, the mean baseline CMT was sig-
nificantly higher in responders (CMT improvement .20%) 
than nonresponders.
We chose to analyze the response of DME after the 
first course of IVB since the BOLT study had shown that 
the majority of eyes demonstrated a response after the first 
course.16 Additionally, an end-point analysis at 12 months 
may lead to the outcomes being dependent on the variability 
in the number of injections received. The BOLT study 
demonstrated that 21% of IVB eyes that did not respond 
to the first course, responded to subsequent courses, with 
these eyes also demonstrating a gain in VA (50% of eyes 
gained .15 letters).16 In our study, “nonresponders” (CMT 
reduction ,20% after the first course of IVB) demonstrated 
similar gains in VA compared to “responders”, also highlight-
ing that persisting edema after the first course of IVB should 
not be used as a criterion for stopping treatment.
Certain OCT morphological features (subretinal fluid 
and integrity of photoreceptor inner and outer segment line 
beneath the fovea) have been shown to be predictive of OCT 
responsiveness for DME treated with intravitreal anti-VEGF 
therapy in small case series.17 However, our findings are 
consistent with a recent large post hoc analysis of data from 
several randomized controlled trials, which found that in 
DME patients receiving monthly injections of ranibizumab, 
OCT morphology was not predictive of poor OCT response. 
In sham-injected eyes, OCT morphology was a predictor of 
poor response, suggesting that anti-VEGF agents can over-
come such features.18
Hypertension is a risk factor for developing diabetic 
retinopathy.19 In our study, hypertension (a diagnosis made 
at baseline) was a statistically significant positive predic-
tor of response after the first course of IVB. The effects of 
antihypertensive medications may have made this group of 
patients more responsive to the effects of IVB; however, 
hypertension has not been found to be a predictive factor 
for VA outcomes in DME patients receiving macular 
laser.20 The effects of different antihypertensive agents in 
the progression of diabetic retinopathy do not appear to be 
class-specific;21 however, future studies on large cohorts 
should determine if they play a role influencing macular 
thickness and VA outcomes after IVB therapy for DME, 
since there is some evidence to suggest that treatment with 
systemic beta-adrenergic blocking agents may reduce the 
need for repeated IVB injections in wet age-related macular 
degeneration.22 It is also possible that some patients in our 
cohort not on antihypertensive medication at baseline could 
have represented untreated hypertensive patients, which 
may have limited the responsiveness to IVB due to contin-
ued hypertension. Indeed, up to 30% of diabetics can have 
undiagnosed/untreated hypertension.23,24 However, treating 
hypertension has not been found to reduce the progression 
to clinically significant DME in patients with established 
retinopathy.21
A recent study found that blood pressure and nephropa-
thy were not predictive of poor response (OCT and visual 
improvement) in DME patients treated with anti-VEGF 
agents, which is consistent with our findings. However, 
Figure 2 Long-term changes in visual acuity after the first intravitreal bevacizumab 
injection in diabetic macular edema responders and nonresponders.
Abbreviation: eTDrs, early Treatment Diabetic retinopathy study.
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in sham-treated patients, these factors were predictive of 
response, suggesting that sustained inhibition of VEGF can 
overcome these poor prognostic features.18
A few studies have looked at the impact of other meta-
bolic parameters in DME response to VEGF inhibition. One 
study looked at the response after a one-dose injection of 
ranibizumab and found that serum HbA1c levels were nega-
tively correlated with the change in CMT.8 Another study 
examined the effects of IVB on CMT at 1 year and found that 
patients with HbA1c levels #7.0% at baseline had greater 
reductions in CMT (statistically significant) than patients 
with a HbA1c level $7.0%.25 We did not find such an effect 
in our patients, although such an effect may be biologically 
plausible. This difference in findings may be due to the way 
we defined responsiveness (CMT change .20%), which may 
be a more robust end point than just examining numerical 
values in the aforementioned studies.
Prior treatment with macula laser was a statistically sig-
nificant predictor of unresponsiveness in our study, which 
does not seem consistent with previous studies. In the BOLT 
study, all patients had prior treatment with laser, but the num-
ber of laser treatments was not associated with the change in 
CMT at 24 months.9 Another study found no difference in 
CMT change after a single injection of IVR in patients who 
had previous treatment for DME versus those that did not; 
however, the former group did have a greater gain in VA.8 
The patients in our cohort who had previous macular laser 
could represent a more treatment-refractory group.
Conclusion
This study demonstrates that systemic hypertension and pre-
vious macular laser were statistically significant positive and 
negative predictors of DME response to IVB, respectively. 
The limitations of our study include its retrospective nature 
and treatment bias. Further studies are needed to determine 
the influence on antihypertensive medications on the respon-
siveness of DME.
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